Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [973]

ASCO 2026: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada

ASCO 2026: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )

Tarlatamab in SCLC shows consistent survival and low immune toxicity across age...

Dr Raymart Macasaet - Monmouth Medical Center, Long Branch, USA

Tarlatamab in SCLC shows consistent survival and low immune toxicity across age groups ( Dr Raymart Macasaet - Monmouth Medical Center, Long Branch, USA )

Tarlatamab improves brain metastases control and survival compared to chemo in...

Dr Giannis Mountzios - The University of Athens, Athens, Greece

Tarlatamab improves brain metastases control and survival compared to chemo in SCLC ( Dr Giannis Mountzios - The University of Athens, Athens, Greece )

Yoga improves mood, fatigue, and insomnia in cancer survivors following...

Dr Karen Mustian - Wilmot Cancer Institute, Rochester, USA

Yoga improves mood, fatigue, and insomnia in cancer survivors following treatment ( Dr Karen Mustian - Wilmot Cancer Institute, Rochester, USA )

Lorlatinib delivers 7-year progression-free survival and durable brain control...

Prof Tony Mok - Chinese University of Hong Kong, Ma Liu Shui, Hong Kong

Lorlatinib delivers 7-year progression-free survival and durable brain control in ALK+ NSCLC ( Prof Tony Mok - Chinese University of Hong Kong, Ma Liu Shui, Hong Kong )

Adjuvant selpercatinib reduces recurrence in RET-positive lung cancer

Dr Jonathan W. Goldman - University of California Los Angeles, Los Angeles, USA

Adjuvant selpercatinib reduces recurrence in RET-positive lung cancer ( Dr Jonathan W. Goldman - University of California Los Angeles, Los Angeles, USA )

Low-dose pembrolizumab plus chemotherapy improves survival and expands access...

Dr Nandini Menon - Tata Memorial Centre, Mumbai, India

Low-dose pembrolizumab plus chemotherapy improves survival and expands access in advanced NSCLC ( Dr Nandini Menon - Tata Memorial Centre, Mumbai, India )

Is radiotherapy a back up plan after neoadjuvant chemo-immunotherapy in...

Dr Daniel Portik - European Organisation for Research and Treatment of Cancer...

Is radiotherapy a back up plan after neoadjuvant chemo-immunotherapy in perioperative lung cancer management? ( Dr Daniel Portik - European Organisation for Research and Treatment of Cancer, Brussels, Belgium )

Perioperative anti–PD-L1 therapy improves event-free survival in resectable...

Prof Yi-Long Wu - Guangdong Lung Cancer Institute, Guangzhou, China

Perioperative anti–PD-L1 therapy improves event-free survival in resectable NSCLC with ctDNA-based risk stratification ( Prof Yi-Long Wu - Guangdong Lung Cancer Institute, Guangzhou, China )

Machine learning models improve prediction of immunotherapy outcomes across...

Dr Alyssa Pybus - Moffitt Cancer Center, Tampa, USA

Machine learning models improve prediction of immunotherapy outcomes across multiple cancer types ( Dr Alyssa Pybus - Moffitt Cancer Center, Tampa, USA )

Setidegrasib shows promising activity in KRAS G12D-mutated advanced NSCLC

Dr Luis Paz-Ares - 12 de Octubre University Hospital, Madrid, Spain

Setidegrasib shows promising activity in KRAS G12D-mutated advanced NSCLC ( Dr Luis Paz-Ares - 12 de Octubre University Hospital, Madrid, Spain )

The potential of T-cell engagers in SCLC treatment

Dr Luis Paz-Ares - 12 de Octubre University Hospital, Madrid, Spain

The potential of T-cell engagers in SCLC treatment ( Dr Luis Paz-Ares - 12 de Octubre University Hospital, Madrid, Spain )

More from ecancer